{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T15:20:36Z","timestamp":1794496836055,"version":"4.9.1"},"reference-count":90,"publisher":"European Respiratory Society (ERS)","issue":"179","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2025,11,2]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>The concept of progressive pulmonary fibrosis (PPF) was developed to facilitate the identification of patients with an interstitial lung disease (ILD) that is worsening and requires treatment. Various criteria have been proposed to identify PPF, generally based on a deterioration in forced vital capacity alone or with worsening of respiratory symptoms and\/or radiological abnormalities. All these criteria are imperfect and based on a limited evidence base. PPF, however it is defined, is associated with high morbidity and mortality. In clinical practice, flexibility is needed in defining ILD progression given differences in the frequencies and methodologies used to monitor patients\u2019 disease. Prompt identification of PPF is important to enable timely initiation or escalation of treatment to slow progression of lung fibrosis, consider eligibility for lung transplantation and provide supportive care as needed. In future, earlier treatment of patients at risk of progression may be possible to improve outcomes for patients.<\/jats:p>","DOI":"10.1183\/16000617.0051-2025","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:35:15Z","timestamp":1774431315000},"page":"250051","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Progressive pulmonary fibrosis: the importance of identification and intervention"],"prefix":"10.1183","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1301-8800","authenticated-orcid":false,"given":"Philip L.","family":"Molyneaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-9149","authenticated-orcid":false,"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2026032502350652000_35.179.250051.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000212"},{"key":"2026032502350652000_35.179.250051.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00692-2018"},{"key":"2026032502350652000_35.179.250051.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2026032502350652000_35.179.250051.4","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in patients with progressive pulmonary fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N Engl J Med"},{"key":"2026032502350652000_35.179.250051.5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026032502350652000_35.179.250051.6","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026032502350652000_35.179.250051.7","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219795"},{"key":"2026032502350652000_35.179.250051.8","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01749-1"},{"key":"2026032502350652000_35.179.250051.9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/resp.14245","article-title":"Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype","volume":"27","author":"Takei","year":"2022","journal-title":"Respirology"},{"key":"2026032502350652000_35.179.250051.10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s12890-024-03247-8","article-title":"Design and baseline characteristics of the ILD-PRO Registry in patients with progressive pulmonary fibrosis","volume":"24","author":"Lobo","year":"2024","journal-title":"BMC Pulm Med"},{"key":"2026032502350652000_35.179.250051.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2026032502350652000_35.179.250051.12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026032502350652000_35.179.250051.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03187-2021"},{"key":"2026032502350652000_35.179.250051.14","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-024-03070-z"},{"key":"2026032502350652000_35.179.250051.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00221-2021"},{"key":"2026032502350652000_35.179.250051.16","doi-asserted-by":"publisher","DOI":"10.1164\/RCCM.202205-0910LE"},{"key":"2026032502350652000_35.179.250051.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202201-0124OC"},{"key":"2026032502350652000_35.179.250051.18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00085-2020"},{"key":"2026032502350652000_35.179.250051.19","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00145-2020"},{"key":"2026032502350652000_35.179.250051.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00752-2023"},{"key":"2026032502350652000_35.179.250051.21","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207252"},{"key":"2026032502350652000_35.179.250051.22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12931-020-01371-7","article-title":"Longitudinal functional changes with clinically significant radiographic progression in idiopathic pulmonary fibrosis: are we following the right parameters?","volume":"21","author":"Taha","year":"2020","journal-title":"Respir Res"},{"key":"2026032502350652000_35.179.250051.23","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.202105-1193ST","article-title":"Patient-centered outcomes research in interstitial lung disease: an official American Thoracic Society research statement","volume":"204","author":"Aronson","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032502350652000_35.179.250051.24","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0055-2023"},{"key":"2026032502350652000_35.179.250051.25","doi-asserted-by":"crossref","first-page":"L600","DOI":"10.1152\/ajplung.00310.2021","article-title":"From pulmonary fibrosis to progressive pulmonary fibrosis: a lethal pathobiological jump","volume":"321","author":"Selman","year":"2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026032502350652000_35.179.250051.26","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.molmed.2023.08.010","article-title":"Pulmonary fibrosis: from pathogenesis to clinical decision-making","volume":"29","author":"Koudstaal","year":"2023","journal-title":"Trends Mol Med"},{"key":"2026032502350652000_35.179.250051.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.09.008"},{"key":"2026032502350652000_35.179.250051.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04507-2020"},{"key":"2026032502350652000_35.179.250051.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01052-2"},{"key":"2026032502350652000_35.179.250051.30","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01879-6"},{"key":"2026032502350652000_35.179.250051.31","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02718-2020"},{"key":"2026032502350652000_35.179.250051.32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01396-2021"},{"key":"2026032502350652000_35.179.250051.33","doi-asserted-by":"crossref","first-page":"1106560","DOI":"10.3389\/fmed.2023.1106560","article-title":"Prognostication of progressive pulmonary fibrosis in connective tissue disease-associated interstitial lung diseases: a cohort study","volume":"10","author":"Chiu","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026032502350652000_35.179.250051.34","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04587-2020"},{"key":"2026032502350652000_35.179.250051.35","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.21037\/jtd-23-481","article-title":"Compare three diagnostic criteria of progressive pulmonary fibrosis","volume":"16","author":"Chen","year":"2024","journal-title":"J Thorac Dis"},{"key":"2026032502350652000_35.179.250051.36","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.202311-2153OC","article-title":"Concordance and prognostic relevance of different definitions of systemic sclerosis interstitial lung disease progression","volume":"210","author":"De Lorenzis","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032502350652000_35.179.250051.37","doi-asserted-by":"crossref","first-page":"106626","DOI":"10.1016\/j.rmed.2021.106626","article-title":"Defining and predicting progression in non-IPF interstitial lung disease","volume":"189","author":"Goos","year":"2021","journal-title":"Respir Med"},{"key":"2026032502350652000_35.179.250051.38","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00308-2016"},{"key":"2026032502350652000_35.179.250051.39","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0840OC"},{"key":"2026032502350652000_35.179.250051.40","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/resp.14579","article-title":"Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis","volume":"28","author":"Maher","year":"2023","journal-title":"Respirology"},{"key":"2026032502350652000_35.179.250051.41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.chest.2025.02.018","article-title":"Changes in lung function and mortality risk in patients with idiopathic pulmonary fibrosis (IPF)","volume":"168","author":"Oldham","year":"2025","journal-title":"Chest"},{"key":"2026032502350652000_35.179.250051.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.07.007"},{"key":"2026032502350652000_35.179.250051.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.11.033"},{"key":"2026032502350652000_35.179.250051.44","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1164\/rccm.202503-0535OC","article-title":"One-year change in quantitative computed tomography is associated with meaningful outcomes in fibrotic lung disease","volume":"211","author":"Koslow","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032502350652000_35.179.250051.45","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1164\/rccm.202501-0208OC","article-title":"A quantitative imaging measure of progressive pulmonary fibrosis","volume":"211","author":"Wang","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032502350652000_35.179.250051.46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12931-019-1020-3","article-title":"The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry","volume":"20","author":"Kreuter","year":"2019","journal-title":"Respir Res"},{"key":"2026032502350652000_35.179.250051.47","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00591-2023"},{"key":"2026032502350652000_35.179.250051.48","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02211-2023"},{"key":"2026032502350652000_35.179.250051.49","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","article-title":"Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management","volume":"35","author":"Wijsenbeek","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2026032502350652000_35.179.250051.50","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/03007995.2020.1860920","article-title":"Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union","volume":"37","author":"Takizawa","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"2026032502350652000_35.179.250051.51","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12931-024-02995-9","article-title":"Treatment patterns and patient journey in progressive pulmonary fibrosis: a cross-sectional survey","volume":"25","author":"Chaudhuri","year":"2024","journal-title":"Respir Res"},{"key":"2026032502350652000_35.179.250051.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103582"},{"key":"2026032502350652000_35.179.250051.53","doi-asserted-by":"crossref","first-page":"100122","DOI":"10.1016\/j.chpulm.2024.100122","article-title":"Remote patient monitoring for managing interstitial lung disease: a mixed-methods process evaluation","volume":"3","author":"Gillett","year":"2024","journal-title":"Chest Pulm"},{"key":"2026032502350652000_35.179.250051.54","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/acr.25346","article-title":"Assessing patient values and preferences to inform the 2023 American College of Rheumatology\/American College of Chest Physicians interstitial lung disease guidelines","volume":"76","author":"Mirza","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026032502350652000_35.179.250051.55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/resp.14656","article-title":"Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: a position statement from the Thoracic Society of Australia and New Zealand 2023 revision","volume":"29","author":"Mackintosh","year":"2024","journal-title":"Respirology"},{"key":"2026032502350652000_35.179.250051.56","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2024.3669"},{"key":"2026032502350652000_35.179.250051.57","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201506-1063ST"},{"key":"2026032502350652000_35.179.250051.58","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/acr.25348","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026032502350652000_35.179.250051.59","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-1113ST"},{"key":"2026032502350652000_35.179.250051.60","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202401-0048PP"},{"key":"2026032502350652000_35.179.250051.61","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00131912"},{"key":"2026032502350652000_35.179.250051.62","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/resp.12931","article-title":"Unclassifiable interstitial lung diseases: clinical characteristics and survival","volume":"22","author":"Hyldgaard","year":"2017","journal-title":"Respirology"},{"key":"2026032502350652000_35.179.250051.63","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1055\/s-0036-1583176","article-title":"Nonspecific interstitial pneumonia: what is the optimal approach to management?","volume":"37","author":"Tomassetti","year":"2016","journal-title":"Semin Respir Crit Care Med"},{"key":"2026032502350652000_35.179.250051.64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12931-024-02731-3","article-title":"Disease trajectories in interstitial lung diseases - data from the EXCITING-ILD registry","volume":"25","author":"Buschulte","year":"2024","journal-title":"Respir Res"},{"key":"2026032502350652000_35.179.250051.65","doi-asserted-by":"crossref","first-page":"17534666211039771","DOI":"10.1177\/17534666211039771","article-title":"Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians","volume":"15","author":"Nambiar","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"2026032502350652000_35.179.250051.66","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/acr.25347","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026032502350652000_35.179.250051.67","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222564"},{"key":"2026032502350652000_35.179.250051.68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00408-024-00778-z","article-title":"Continued treatment with nintedanib in patients with progressive pulmonary fibrosis: data from INBUILD-ON","volume":"203","author":"Wuyts","year":"2025","journal-title":"Lung"},{"key":"2026032502350652000_35.179.250051.69","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202009-3608ST"},{"key":"2026032502350652000_35.179.250051.70","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0101-2023"},{"key":"2026032502350652000_35.179.250051.71","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-1066ST"},{"key":"2026032502350652000_35.179.250051.72","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0012-2024"},{"key":"2026032502350652000_35.179.250051.73","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0027-2024"},{"key":"2026032502350652000_35.179.250051.74","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12931-024-02997-7","article-title":"Patient-centered care in pulmonary fibrosis: access, anticipate, and act","volume":"25","author":"Hofman","year":"2024","journal-title":"Respir Res"},{"key":"2026032502350652000_35.179.250051.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.07.005"},{"key":"2026032502350652000_35.179.250051.76","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00422-2021"},{"key":"2026032502350652000_35.179.250051.77","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215731"},{"key":"2026032502350652000_35.179.250051.78","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02146-2021"},{"key":"2026032502350652000_35.179.250051.79","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2024-002368"},{"key":"2026032502350652000_35.179.250051.80","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02571-2021"},{"key":"2026032502350652000_35.179.250051.81","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00577-2022"},{"key":"2026032502350652000_35.179.250051.82","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41467-023-37193-6","article-title":"Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts","volume":"14","author":"Adegunsoye","year":"2023","journal-title":"Nat Commun"},{"key":"2026032502350652000_35.179.250051.83","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005964"},{"key":"2026032502350652000_35.179.250051.84","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S2213-2600(17)30349-1","article-title":"Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study","volume":"5","author":"Herazo-Maya","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026032502350652000_35.179.250051.85","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00408-024-00742-x","article-title":"Utility of the 52-gene risk score to identify patients with idiopathic pulmonary fibrosis at greater risk of mortality in the era of antifibrotic therapy","volume":"202","author":"S\u00f6llner","year":"2024","journal-title":"Lung"},{"key":"2026032502350652000_35.179.250051.86","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(21)00503-8","article-title":"Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis","volume":"10","author":"Bowman","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026032502350652000_35.179.250051.87","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.chest.2024.10.042","article-title":"The dawn of precision medicine in fibrotic interstitial lung disease","volume":"167","author":"Karampitsakos","year":"2025","journal-title":"Chest"},{"key":"2026032502350652000_35.179.250051.88","doi-asserted-by":"crossref","first-page":"27115","DOI":"10.1038\/s41598-025-12952-1","article-title":"Circulating biomarkers in patients with progressive fibrosing interstitial lung disease treated with nintedanib: a pilot study","volume":"15","author":"Miceli","year":"2025","journal-title":"Sci Rep"},{"key":"2026032502350652000_35.179.250051.89","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1016\/j.acra.2024.05.005","article-title":"Usefulness of CT quantification-based assessment in defining progressive pulmonary fibrosis","volume":"31","author":"Ahn","year":"2024","journal-title":"Acad Radiol"},{"key":"2026032502350652000_35.179.250051.90","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.1007\/s00330-025-11714-x","article-title":"Risk factors and prognostic indicators for progressive fibrosing interstitial lung disease: a deep learning-based CT quantification approach","volume":"35","author":"Lee","year":"2025","journal-title":"Eur Radiol"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0051-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:35:20Z","timestamp":1774431320000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0051-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":90,"journal-issue":{"issue":"179","published-online":{"date-parts":[[2026,3,25]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1183\/16000617.0051-2025"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0051-2025","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1183\/16000617.0051-2025.supp1","asserted-by":"subject"}]},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}